Clinical trials
Plaque Psoriasis clinical trials
Below are recruiting plaque psoriasis clinical trials, each written for real people, not researchers. We’re tracking 53 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07337434RecruitingEarly Phase 1
Comparing two pills for moderate to severe psoriasis
This trial tests two oral medications, Apremilast and Methotrexate, to see which works better for people with moderate to severe plaque psoriasis. You must not have taken systemic treatments (pills or shots that work throughout the body) in the last 3 months.
Peshawar, Khyber PukhtunkhwaAges 18–60 - NCT04347473RecruitingPhase 4
ILUMYA plus halobetasol ointment for plaque psoriasis
This trial studies whether ILUMYA (an injection) working together with halobetasol ointment helps control moderate-to-severe plaque psoriasis. It is meant for adults whose psoriasis is significant enough that they may need light therapy (phototherapy) and/or pills/injections (systemic therapy).
East Windsor, New JerseyAges 18 years+ - NCT03827876RecruitingPhase 4
Enstilar added to Enbrel or Humira for plaque psoriasis
This trial tests whether adding Enstilar (a skin spray/foam medication) on top of your usual injection—Enbrel or Humira—works better for plaque psoriasis. You might be a candidate if your psoriasis affects a moderate amount of skin and you’ve been on Enbrel or Humira long enough.
East Windsor, New JerseyAges 18 years+ - NCT07243782Recruiting
Study of Cosentyx for skin and joint conditions in Korea
This study tracks how well Cosentyx works in real-world use for people with hidradenitis suppurativa, plaque psoriasis, or juvenile idiopathic arthritis. It helps doctors understand the medicine's long-term effects in Korean patients.
Seoul, SeoulAges 6–100 - NCT07410793RecruitingPhase 2
Acupuncture plus herbal cream vs standard cream for plaque psoriasis
This trial tests if adding a Chinese herbal cream to acupuncture works as well as adding a standard psoriasis cream (calcipotriol) to acupuncture. It's for people with mild to moderate plaque psoriasis and may offer a natural treatment option.
Muang, ChiangraiAges 18–65 - NCT04036188RecruitingEarly Phase 1
Vitamin D and triamcinolone for plaque psoriasis
This early study tests whether taking vitamin D together with triamcinolone (a steroid used on skin) works better for plaque psoriasis than a standard approach. It aims to see if the combination helps clear psoriasis plaques and is safe.
Fairborn, OhioAges 18 years+ - NCT05642182RecruitingPhase 1
Study drug trial for mild to moderate plaque psoriasis
This Phase 1 study tests a new drug (SFA002) in adults with stable plaque psoriasis. It mainly focuses on safety and how the body responds, and may eventually help people with psoriasis plaques.
Pompano Beach, FloridaAges 18 years+ - NCT07116967RecruitingPhase 3
Long-term safety of two psoriasis drugs in people with heart risk
This study compares two medications for psoriasis (deucravacitinib and ustekinumab) over a long period. It's designed for people with moderate-to-severe psoriasis who also have certain risk factors for heart disease, like high blood pressure or diabetes.
Birmingham, AlabamaAges 40 years+ - NCT03987763RecruitingPhase 4
Study of psoriasis lotion safety in children ages 6–16
This trial tests how safe and how the body handles (pharmacokinetics) a psoriasis lotion called IDP-122 when used in children with plaque psoriasis. You may be able to join if your child has a suitable amount of plaque psoriasis and can follow safety rules during the study.
Fountain Valley, CaliforniaAges 6–17 - NCT05744466Recruiting
Compare two psoriasis medicines using real-world patient data
This study looks at how well two common plaque psoriasis medicines—deucravacitinib and apremilast—work in everyday care. It may help researchers understand which option performs better in real patients outside of a traditional drug trial.
Waltham, MassachusettsAges 18 years+ - NCT06477237RecruitingPhase 3
Testing a new psoriasis shot for moderate to severe plaque
This trial tests a new medication called HB0017 for moderate to severe plaque psoriasis. It aims to see if it is safe and effective in reducing skin symptoms and improving quality of life.
Jiangmen, GuangdongAges 18–75 - NCT07489885RecruitingPhase 2
Study of D-2570 for moderate to severe plaque psoriasis
This trial tests an experimental drug, D-2570, for people with moderate to severe plaque psoriasis. It aims to see if the medication can safely improve skin symptoms.
Birmingham, AlabamaAges 18–70 - NCT07261306RecruitingEarly Phase 1
Methotrexate vs tofacitinib pills for plaque psoriasis
This study compares two oral pill treatments—methotrexate and tofacitinib—for people with chronic plaque psoriasis that is moderate to severe and hasn't responded well to creams. The goal is to see which pill works better at clearing skin.
Lahore, Punjab ProvinceAges 18–70 - NCT07265284RecruitingPhase 3
IBI112 for teens with moderate to severe plaque psoriasis
This study tests a new medicine called IBI112 for teens aged 12–18 with moderate to severe plaque psoriasis. It aims to see if the medicine is safe and can help clear skin better than placebo.
Beijing, Beijing MunicipalityAges 12–18 - NCT07532486Recruiting
Guselkumab dosing study for moderate-to-severe psoriasis
This study tests whether a higher dose of guselkumab (a biologic medicine) given less frequently works as well as the standard dose for treating moderate-to-severe plaque psoriasis. The goal is to find a dosing schedule that is both effective and convenient for patients.
Hangzhou, ZhejiangAges 18 years+ - NCT07683065Recruiting
Secukinumab treatment in psoriasis patients with liver condition
This study looks at how well secukinumab works for psoriasis patients who also have a type of fatty liver disease called MASLD. It may help doctors understand if this treatment is a good option for people with both conditions.
Badalona, BarcelonaAges 18–100 - NCT07582783Recruiting
Treatment Persistence with Guselkumab for Moderate-to-Severe Plaque Psoriasis
This study tracks how well patients stick with guselkumab, a biologic injection medication for moderate-to-severe plaque psoriasis. Researchers want to understand real-world treatment outcomes in Romania to help improve psoriasis care.
BârladAges 18 years+ - NCT06701513Recruiting
Real-world study of deucravacitinib for plaque psoriasis
This study looks at how well deucravacitinib works for adults with moderate to severe plaque psoriasis in everyday medical practice. It helps doctors understand the real-world benefits of this treatment.
AmiensAges 18 years+ - NCT06999941Enrolling by invitation
Study of deucravacitinib for psoriasis with eczema features
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06742333RecruitingPhase 2
Can bimekizumab delay early plaque psoriasis?
This trial tests if the drug bimekizumab can slow down chronic inflammation in people with early plaque psoriasis. It's for adults 18-44 with mild psoriasis who haven't used topical treatments recently.
Nice, Alpes-MaritimesAges 18–45 - NCT07511647RecruitingPhase 3
Study of QL2106 for moderate to severe plaque psoriasis
This trial tests an injectable drug, QL2106, for people with moderate to severe plaque psoriasis. It may help if you are a candidate for light therapy or other systemic treatments.
Jining, ShandongAges 18 years+ - NCT06912165RecruitingPhase 2
WD-890 for moderate to severe plaque psoriasis
This study tests an investigational drug called WD-890 for people with moderate-to-severe plaque psoriasis that hasn't responded well enough to other treatments. It may help reduce skin patches, scaling, and itching.
Nanjing, JiangsuAges 18–70 - NCT07663331RecruitingPhase 4
Adalimumab for adults with non-infectious uveitis
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06888193RecruitingPhase 1
Bimekizumab in breast milk of mothers being treated
This study measures how much bimekizumab (Bimzelx) gets into breast milk. It helps us understand if the medicine is safe for breastfeeding babies whose mothers take this drug.
Santa Monica, CaliforniaAges 18 years+
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for plaque psoriasis?
- Yes. Clin2 currently lists 53 recruiting plaque psoriasis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a plaque psoriasis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a plaque psoriasis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.